These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24118041)

  • 21. Allosteric regulation of biosynthetic threonine deaminase from Escherichia coli: effects of isoleucine and valine on active-site ligand binding and catalysis.
    Eisenstein E
    Arch Biochem Biophys; 1995 Jan; 316(1):311-8. PubMed ID: 7840631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in G protein-coupled receptor allostery: from function to structure.
    Christopoulos A
    Mol Pharmacol; 2014 Nov; 86(5):463-78. PubMed ID: 25061106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of fluctuations in ligand binding cooperativity of membrane receptors.
    Zhu L; Frenkel D; Bolhuis PG
    Phys Rev Lett; 2011 Apr; 106(16):168103. PubMed ID: 21599417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.
    Harms BD; Kearns JD; Su SV; Kohli N; Nielsen UB; Schoeberl B
    Methods Enzymol; 2012; 502():67-87. PubMed ID: 22208982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular dynamics simulation studies on the positive cooperativity of the Kemptide substrate with protein kinase A induced by the ATP ligand.
    Li C; Ma N; Wang Y; Wang Y; Chen G
    J Phys Chem B; 2014 Feb; 118(5):1273-87. PubMed ID: 24456306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor.
    Fleck BA; Hoare SR; Pick RR; Bradbury MJ; Grigoriadis DE
    J Pharmacol Exp Ther; 2012 May; 341(2):518-31. PubMed ID: 22357972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for positive allosteric modulators: assessment of modulator concentration-response curves as a screening paradigm.
    Langmead CJ
    J Biomol Screen; 2007 Aug; 12(5):668-76. PubMed ID: 17478477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dimerization-based control of cooperativity.
    Bouhaddou M; Birtwistle MR
    Mol Biosyst; 2014 Jul; 10(7):1824-32. PubMed ID: 24736836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor.
    Heitman LH; Ye K; Oosterom J; Ijzerman AP
    Mol Pharmacol; 2008 Jun; 73(6):1808-15. PubMed ID: 18344315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Binding techniques to study the allosteric energy cycle.
    Kranz JK; Clemente JC
    Methods Mol Biol; 2012; 796():3-17. PubMed ID: 22052482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using competition assays to quantitatively model cooperative binding by transcription factors and other ligands.
    Peacock J; Jaynes JB
    Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt A):2789-2801. PubMed ID: 28774855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Half-site reactivity, negative cooperativity, and positive cooperativity: quantitative considerations of a plausible model.
    Bloom CR; Kaarsholm NC; Ha J; Dunn MF
    Biochemistry; 1997 Oct; 36(42):12759-65. PubMed ID: 9335532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.
    Vauquelin G; Hall D; Charlton SJ
    Br J Pharmacol; 2015 May; 172(9):2300-15. PubMed ID: 25537684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Avidity observed between a bivalent inhibitor and an enzyme monomer with a single active site.
    Lacham-Hartman S; Shmidov Y; Radisky ES; Bitton R; Lukatsky DB; Papo N
    PLoS One; 2021; 16(11):e0249616. PubMed ID: 34847142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unusual binding stoichiometries and cooperativity are observed during binary and ternary complex formation in the single active pore of R67 dihydrofolate reductase, a D2 symmetric protein.
    Bradrick TD; Beechem JM; Howell EE
    Biochemistry; 1996 Sep; 35(35):11414-24. PubMed ID: 8784197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures.
    Annis DA; Nazef N; Chuang CC; Scott MP; Nash HM
    J Am Chem Soc; 2004 Dec; 126(47):15495-503. PubMed ID: 15563178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hybrid ortho/allosteric ligands for the adenosine A(1) receptor.
    Narlawar R; Lane JR; Doddareddy M; Lin J; Brussee J; Ijzerman AP
    J Med Chem; 2010 Apr; 53(8):3028-37. PubMed ID: 20345101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dualsteric muscarinic antagonists--orthosteric binding pose controls allosteric subtype selectivity.
    Schmitz J; van der Mey D; Bermudez M; Klöckner J; Schrage R; Kostenis E; Tränkle C; Wolber G; Mohr K; Holzgrabe U
    J Med Chem; 2014 Aug; 57(15):6739-50. PubMed ID: 25051097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays.
    Kaufman EN; Jain RK
    Cancer Res; 1992 Aug; 52(15):4157-67. PubMed ID: 1638531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A method to calculate binding equilibrium concentrations in the allosteric ternary complex model that supports ligand depletion.
    Gnacadja G
    Math Biosci; 2011 Aug; 232(2):135-41. PubMed ID: 21645524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.